ニホン ノ ADR ワカイ チョウテイ ノ アジア ヘノ ハッシン インドネシア ワカイ チョウテイ セイド キョウカ シエン プロジェクト ノ ジッシ ニツイテ

I had　taken　part　from　2007　ti112009　in　the　technical　legal　assitance “Project　for　strengthening　Settlement　and　Mediation　in　lndonesia”by Japanese　Government（Japan　International　Cooperation　Agency）as　a short　term　expert．　Because　Indonesian　Settlement　alld　mediation system　did　not　work．　Indonesian　Supreme　Court　offered　to　reform　old Supreme　Court　Regulation　by　introducing　the　strong　points　of Japanese　Wakai　and　Chotei　system　and　to　lead　judge’s　skill　improved． We，　the　experts　who　involve　the　project，　made　the　new　Supreme　Court Regulation　which　introduced　the　strong　points　of　Japanese　system　and provided　training　system　of　Judge　and　court　clerk．　But　the　project term　was　ended　at　this　point．　The　person　related　to　the　Japanese　side and　Indonesia　side　who　had　actually　taken　charge　to　this　project　hoped for　the　continuation　of　this　project．　But　this　hope　was　not　admitted． This　paper　is　the　report　on　the　outline　and　the　problem　of　this　project

ワカイ ギジュツロン

講

High-resolution spectroscopy and single-photon Rydberg excitation of reconfigurable ytterbium atom tweezer arrays utilizing a metastable state

We present an experimental system for Rydberg tweezer arrays with ytterbium (Yb) atoms featuring internal state manipulation between the ground ${}^1$S$_0$ and the metastable ${}^3$P$_2$ states, and single-photon excitation from the ${}^3$P$_2$ to Rydberg states. In the experiments, single Yb atoms are trapped in two-dimensional arrays of optical tweezers and are detected by fluorescence imaging with the intercombination ${}^1$S$_0 \leftrightarrow {}^3$P$_1$ transition, and the defect-free single atom arrays are prepared by the rearrangement with the feedaback. We successfully perform high-resolution ${}^1$S$_0\leftrightarrow {}^3$P$_2$ state spectroscopy for the single atoms, demonstrating the utilities of this ultranarrow transition. We further perform single-photon excitation from the ${}^3$P$_2$ to Rydberg states for the single atoms, which is a key for the efficient Rydberg excitation. We also perform a systematic measurement of a complex energy structure of a series of D states including newly observed ${}^3$D$_3$ states. The developed system shows feasibility of future experiments towards quantum simulations and computations using single Yb atoms.Comment: 10 pages, 9 figure

Case report: Strong GAD antibody positivity and type 1 diabetes-HLA-susceptible haplotype-DRB1*04:05-DQB1*04:01 in a Japanese patient with immune checkpoint inhibitor-induced type 1 diabetes

Immune checkpoint inhibitors (ICIs) are widely used in cancer treatment; however, they can lead to immune-related adverse events, including immune checkpoint inhibitor-induced type 1 diabetes mellitus (ICI-T1DM). While fulminant T1DM is common in East Asia, ICI-T1DM has predominantly been reported in Western countries. In this report, we present the case of a 66-year-old Japanese man with type 2 diabetes mellitus undergoing dialysis for diabetic nephropathy. The patient was diagnosed with left upper lobe lung cancer, and treatment with nivolumab and ipilimumab was initiated. After 48 days, the patient experienced impaired consciousness and difficulty moving. His blood glucose levels were 815 mg/dL, and metabolic acidosis was detected, leading to a diagnosis of diabetic ketoacidosis. The patient was subsequently treated with continuous intravenous insulin. However, his C-peptide levels rapidly depleted, and new-onset ICI-T1DM was diagnosed. Although most Japanese patients with ICI-T1DM test negative for glutamic acid decarboxylase (GAD) antibodies, this case exhibited a strong positivity. Thus, we reviewed the literature on 15 similar Japanese cases, revealing a mean HbA1c level at onset of 8.7% and a mean time from ICI administration to onset of 9.7 weeks, which was shorter than that in GAD-negative cases. Moreover, human leukocyte antigen typing revealed five cases of DRB1*04:05-DQB1*04:01, including the present case, and one case of DRB1*09:01-DQB1*03:03, both of which were susceptible to T1DM haplotypes. These findings suggest that GAD antibody positivity may be associated with acute onset and disease progression in some cases of Japanese patients with ICI-T1DM. Given that the prediction of new-onset ICI-T1DM is challenging, monitoring GAD antibody levels might be useful. However, further studies with large sample sizes and validation across different racial and ethnic populations are warranted

Design and baseline characteristics of the finerenone in reducing cardiovascular mortality and morbidity in diabetic kidney disease trial

Background: Among people with diabetes, those with kidney disease have exceptionally high rates of cardiovascular (CV) morbidity and mortality and progression of their underlying kidney disease. Finerenone is a novel, nonsteroidal, selective mineralocorticoid receptor antagonist that has shown to reduce albuminuria in type 2 diabetes (T2D) patients with chronic kidney disease (CKD) while revealing only a low risk of hyperkalemia. However, the effect of finerenone on CV and renal outcomes has not yet been investigated in long-term trials. Patients and Methods: The Finerenone in Reducing CV Mortality and Morbidity in Diabetic Kidney Disease (FIGARO-DKD) trial aims to assess the efficacy and safety of finerenone compared to placebo at reducing clinically important CV and renal outcomes in T2D patients with CKD. FIGARO-DKD is a randomized, double-blind, placebo-controlled, parallel-group, event-driven trial running in 47 countries with an expected duration of approximately 6 years. FIGARO-DKD randomized 7,437 patients with an estimated glomerular filtration rate >= 25 mL/min/1.73 m(2) and albuminuria (urinary albumin-to-creatinine ratio >= 30 to <= 5,000 mg/g). The study has at least 90% power to detect a 20% reduction in the risk of the primary outcome (overall two-sided significance level alpha = 0.05), the composite of time to first occurrence of CV death, nonfatal myocardial infarction, nonfatal stroke, or hospitalization for heart failure. Conclusions: FIGARO-DKD will determine whether an optimally treated cohort of T2D patients with CKD at high risk of CV and renal events will experience cardiorenal benefits with the addition of finerenone to their treatment regimen. Trial Registration: EudraCT number: 2015-000950-39; ClinicalTrials.gov identifier: NCT02545049

Wakai : Terobosan Baru Penyelesaian Sengketa

215

Wakai: terobosan baru penyelesaian sengketa

Buku ini menyorot malsah penyelesaian suatu sengketa/perselisihan. Buku ini memberikan solusi bagimana upaya penyelesaian sengketa melalui mediasi, baik yang court connected mediation maupun mediasi di luar pengadila

Wakai : penyelesaian sengketa ala Jepang

204 hal.; 21 cm